Pirozynski 1996.

Methods	Study Design: Parallel RCT Randomisation: random stated, method not described Concealment of Allocation: Not stated Double Blinding: Yes Withdrawals / dropouts: Described Adverse events: Not described Statistical analysis: Not described Jadad Score: 3
Participants	Study site: Not stated No eligible: Not stated No randomised: 262 No completed: 23 withdrew due to exacerbation or adverse event, ? number completed. Sex: Females: 143 (55%); Males: 119 (45%) Age: Mean 36yrs Diagnostic criteria for asthma: Not stated Inclusion criteria: Not stated Exclusion criteria: Not stated Baseline severity of asthma: mild‐to‐moderate asthma. Mean FEV1 % predicted: 82.3%. Mean PEF: 380 L/min
Interventions	1: BUD 800mcg/day (400mcg bd) for 4 weeks then reduced to 200mcg/day (100mcg bd) for a further 8 weeks 2: BUD 200mcg/day (100mcg bd) for 12 weeks Delivery device: DPI Duration of treatment: 12 weeks Run in phase: 2 weeks Other:
Outcomes	Withdrawal due to exacerbations or adverse events, PEF, FEV1, rescue medications, symptoms
Notes	Abstract only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised; other information not available